Preparation and immune activity analysis of H5N1 subtype avian influenza virus recombinant protein-based vaccine

Poultry Science

Volumn 88, Issue 8, 2009, Pages 1608-1615

  Xie, Q M ^a   Ji, J ^a   Du, L Q ^a   Cao, Y C ^b   Wei, L ^c   Xue, C Y ^b   Qin, J P ^a   Ma, J Y ^a   Bi, Y Z ^b  

^a SOUTH CHINA AGRICULTURAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c Beijing Municipal Academy of Agriculture and Forestry Sciences   (China)

Author keywords

H5N1 subtype avian influenza virus; Hemagglutinin; Immune activity; Recombinant protein based vaccine

Indexed keywords

AVES; AVIAN INFLUENZA VIRUS; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; INFLUENZA A VIRUS; INFLUENZAVIRUS A; ORTHOMYXOVIRIDAE;

EID: 68849097242     PISSN: 00325791     EISSN: 15253171     Source Type: Journal    
DOI: 10.3382/ps.2009-00092     Document Type: Article

References (30)

1. Air, G. M., and W. G. Laver. 1989. The neuraminidase of influenza virus. Proteins 6:341-356.
2. Austin, C. 2003. Novel approach to obtain biologically active recombinant heterodimeric proteins in Escherichia coli. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 786:93-107.
3. Banks, J., E. S. Speidel, E. Moore, L. Plowright, A. Piccirillo, and I. Capua. 2001. Changes in the haemagglutinin and the neuraminidase genes prior to the emergence of highly pathogenic H7N1 avian influenza viruses in Italy. Arch. Virol. 146:963-973.
4. Cabrita, L. D., D. Weiwen, and P. B. Stephen. 2006. A family of E. coli expression vectors for laboratory scale and high throughput soluble protein production. BMC Biotechnol. 6:12.
5. Capua, I., and D. J. Alexander. 2006. The challenge of avian influenza to the veterinary community. Avian Pathol. 35:189-205.
6. Capua, I., and D. J. Alexander. 2007. Animal and human health implications of avian influenza infections. Biosci. Rep. 27:359-372.
7. Faulkner, L., G. Buchan, L. Slobbe, E. Lockhart, J. Wales, M. Wilson, and M. Baird. 2003. Influenza hemagglutinin peptides fused to interferon gamma and encapsulated in liposomes protects mice against influenza infection. Vaccine 21:932-939.
8. Fouchier, R. A., V. Munster, A. Wallensten, T. M. Bestebroer, S. Herfst, and D. Smith. 2005. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J. Virol. 79:2814-2822.
9. Gambotto, A., S. M. Barratt-Boyes, M. D. De Jong, G. Neumann, and Y. Kawaoka. 2008. Human infection with highly pathogenic H5N1 influenza virus. Lancet 371:1464-1475.
10. Garcia, M., J. M. Crawford, J. W. Latimer, E. Rivera-Cruz, and M. L. Perdue. 1996. Heterogeneity in the haemagglutinin gene and emergence of the highly pathogenic phenotype among recent H5N2 avian influenza viruses from Mexico. J. Gen. Virol. 77:1493-1504.
11. Huber, V. C., and J. A. McCullers. 2008. Vaccines against pandemic influenza: What can be done before the next pandemic? Pediatr. Infect. Dis. J. 27 (Suppl. 10):113-117.
12. Ignjatovic, J., and P. G. McWaters. 1991. Monoclonal antibodies to three structural proteins of avian infectious bronchitis virus: Characterization of epitopes and antigenic differentiation of Australian strains. J. Gen. Virol. 72:2915-2922.
13. Johansson, B. E., D. J. Bucher, and E. D. Kilbourne. 1989. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J. Virol. 63:1239-1246.
14. Montomoli, E., and I. Manini. 2007. Pre-emptive vaccination against pandemic influenza virus. Vaccine 25:1921-1922.
15. Nallamsetty, S., and D. S. Waugh. 2006. Solubility-enhancing proteins MBP and NusA play a passive role in the folding of their fusion partners. Protein Expr. Purif. 45:175-182.
16. Nilsson, J., D. Nilsson, Y. Williams, L. Pettersson, M. Uhlen, and P. A. Nygren. 1994. Competitive elution of protein A fusion allows specific recovery under mild conditions. Eur. J. Biochem. 224:103-108.
17. Perdue, M. L., and D. E. Swayne. 2005. Public health risk from avian influenza viruses. Avian Dis. 49:317-327.
18. Sahdev, S., S. K. Khattar, and S. S. Kulvinder. 2008. Production of active eukaryotic proteins through bacterial expression systems: A review of the existing biotechnology strategies. Mol. Cell. Biochem. 307:249-264.
19. Sambhara, S., and G. A. Poland. 2006. Avian influenza vaccines: What's all the flap? Lancet 367:1636-1638.
20. Skehel, J. J., and D. C. Wiley. 2000. Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu. Rev. Biochem. 69:531-569.
21. Su, Y., Z. R. Zou, S. Y. Feng, P. Zhou, and L. J. Cao. 2007. The acidity of protein fusion partners predominantly determines the efficacy to improve the solubility of the target proteins expressed in Escherichia coli. J. Biotechnol. 129:373-382.
22. Suarez, D. L., D. A. Senne, J. Banks, I. H. Brown, S. C. Essen, and C. W. Lee. 2004. Recombination resulting in virulence shift in avian influenza outbreak. Emerg. Infect. Dis. 10:693-699.
23. Thierry, V. D. B., L. Benedicte, M. Sylvie, V. B. Steven, and B. Michel. 2008. Influenza vaccines and vaccination strategies in birds. Comp. Immunol. Microbial. Infect. Dis. 31:121-165.
24. Treanor, J. J., J. D. Campbell, K. M. Zangwill, T. Rowe, and W. Mark. 2007. Safety and immunogenicity of a baculovirusexpressed hemagglutinin influenza vaccine: A randomized controlled trial. JAMA 297:1577-1582.
25. Walsh, G., and R. Jefferis. 2006. Post-translational modifications in the context of therapeutic proteins. Nat. Biotechnol. 24:1241-1252.
26. Wang, K. Y., M. H. Kathleen, A. Karl, C. Richard, M. Wafaa, and M. J. C. Manon. 2006. Expression and purification of an influenza hemagglutinin-One step closer to a recombinant protein-based influenza vaccine. Vaccine 24:2176-2185.
27. Wood, J. M., and J. S. Robertson. 2004. From lethal virus to lifesaving vaccine: Developing inactivated vaccines for pandemic influenza. Nat. Rev. Microbiol. 2:842-847.
28. Yang, D. G., Y. C. Chung, Y. K. Lai, C. W. Lai, H. J. Liu, and H. Y. Chen. 2007. Avian influenza virus hemagglutinin display on baculovirus envelope: Cytoplasmic domain affects virus properties and vaccine potential. Mol. Ther. 15:989-996.
29. Yang, H. J., J. Zhang, and W. X. Luo. 2003. Establishment and application of a high efficiency stable secretory prokaryotic expression vector. J. Xiamen Univ. 42:410-415. (In Chinese, abstract in English)
30. Zhang, R. H., M. L. Jin, G. H. Wang, Z. J. Yu, S. T. Zhao, H. C. Li, Y. D. Tan, and H. C. Chen. 2005. Expression of hemagglutinin of avian influenza virus (AIV) and its application in diagnosis of AIV H9 subtype. J. Chin. Biotechnol. 21:315-319. (In Chinese, abstract in English)